throbber
CENTER FOR DRUG EVALUATION AND
`
`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`RESEARCH
`
`
`
`
`
`APPLICATION NUMBER:
`22-264
`22-264
`
`APPLICA TION NUMBER:
`
`CHEMISTRY REVIEW(S)
`CHEMISTRY REVIEW! S}
`
`
`
`
`
`
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`CHEMISTRY REVIEW
`
`NDA 22-264
`
`
`INVEGA® SUSTENNA
`(paliperidone palmitate extended release injectable suspension)
`
`
`Janssen Pharmaceutica N.V.
`
`
`Review #2
`
`David J. Claffey, Ph.D.
`ONDQA
`
`
`
`
`
`
`
`
`
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`
`
`
`Table of Contents
`
`
`Table of Contents .....................................................................................................2
`
`Chemistry Review Data Sheet.................................................................................3
`
`The Executive Summary .........................................................................................8
`
`I. Recommendations .......................................................................................................................8
`A. Recommendation and Conclusion on Approvability.......................................................................8
`B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
`Management Steps, if Approvable...................................................................................................8
`
`II. Summary of Chemistry Assessments.........................................................................................8
`A. Description of the Drug Product(s) and Drug Substance(s) .............................................................8
`B. Description of How the Drug Product is Intended to be Used........................................................13
`C. Basis for Approvability or Not-Approval Recommendation..........................................................13
`
`III. Administrative.........................................................................................................................14
`A. Reviewer’s Signature......................................................................................................................14
`B. Endorsement Block.........................................................................................................................14
`C. CC Block ........................................................................................................................................14
`
`Chemistry Assessment.......................................................................................... 15
`S
` DRUG SUBSTANCE...................................................................................................................22
`P
` DRUG PRODUCT........................................................................................................................30
`
`II. Review Of Common Technical Document-Quality (Ctd-Q) Module 1 ..................................34
`A. Labeling & Package Insert ............................................................................................................34
`B. Environmental Assessment Or Claim Of Categorical Exclusion ...................................................34
`
`
`
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`
`Chemistry Review Data Sheet
`
`
`
`
`1. NDA 22-264
`
`
`2. REVIEW #:2
`
`
`3. REVIEW DATE: 20 JUL 2009
`
`
`4. REVIEWER: David J. Claffey, PhD
`
`
`
`5. PREVIOUS DOCUMENTS:
`
`
`Previous Documents
`IND 67,356
`Original NDA
`Amendment (BC)
`Amendment (BC)
`Amendment (BL)
`Amendment (BC)
`
`
`
`
`
`
`
`
`
`
`6. SUBMISSION(S) BEING REVIEWED:
`
`
`Submission(s) Reviewed
`Amendment N-0026
`Amendment N-0028
`Amendment N-0033
`Amendment N-0038
`Amendment N-0039
`Amendment N-0040
`Amendment N-0041
`
`
`
`
`
`
`Page of 55 3
`
`Document Date
`6 MAY 2003
`26 OCT 2007
`26 MAY 2008
`13 JUN 2008
`2 JUL 2008
`11 JUL 2008
`
`Document Date
`3 FEB 2009
`
`24 FEB 2009
`22 MAY 2009
`16 JUL 2009
`17 JUL 2009
`20 JUL 2009
`20 JUL 2009
`
`
`

`

`
`7. NAME & ADDRESS OF APPLICANT:
`
`
`
`
`
`
`
`
`
`
`Name:
`
`Address:
`
`Representative:
`
`Telephone:
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`Janssen, L.P.
`Johnson & Johnson Pharmaceutical Research &
`Development, LLC
`Office 12607, 1125 Trenton-Harbourton Road,
`Titusville, NJ 08560
`
`
`Kelly Ward (for CMC related issues)
`
`609-730-2056
`
`
`8. DRUG PRODUCT NAME/CODE/TYPE:
`
`
`a) Proprietary Name: INVEGA® SUSTENNA
`b) Non-Proprietary Name (USAN): Paliperidone palmitate
`c) Code Name/# (ONDC only): JNJ16977831; R092670
`d) Chem. Type/Submission Priority (ONDC only):
`• Chem. Type: 2
`• Submission Priority: S
`
`
`
`9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)
`
`
`10. PHARMACOL. CATEGORY: Antipsychotic
`
`
`
`11. DOSAGE FORM:
`
`
`12. STRENGTH/POTENCY: 39 mg, 78 mg, 117 mg, 156 and 234 mg of
`paliperidone palmitate (data for
` strength was provided but applicant is not
`seeking approval for this strength at this time).
`
`
`
`13. ROUTE OF ADMINISTRATION: Intramuscular
`
`
`
`
` extended release injectable suspension
`
`
`
`Page of 55 4
`
`(b) (4)
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`14. Rx/OTC DISPENSED: _x__Rx ___OTC
`
`
`15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
` SPOTS product – Form Completed
`
` x Not a SPOTS product
`
`
`
`
`
`
`
`
`
`
`
`16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR
`FORMULA, MOLECULAR WEIGHT:
`(9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-
`tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate
`(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl4-oxo-
`4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate
`
`Empirical formula: C39H57FN4O4
`
`
`
`Molecular weight: 664.89
`
`
`
`17. RELATED/SUPPORTING DOCUMENTS:
`
`
`A. DMFs:
`
`
`
`DMF
`#
`
`TYPE HOLDER
`
`ITEM
`REFERENCED
`
`CODE1
`
`STATUS2
`
`DATE
`REVIEW
`COMPLETED
`
`COMMENTS
`
`
`
`Page of 55 5
`
`

`

`
`
`
`
`
`II
`
`20902
`
`18915
`
`II
`
`III
`III
`
`III
`
`III
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`Janssen
`Pharmaceutic
`a,
`N.V.
`
`Janssen
`Pharmaceutic
`a,
`N.V.
`
`Paliperidone
`palmitate as
`manufactured in
`Beerse and Cork,
`Ireland
`Belgium
`Paliperidone
`(R076477
`“crude”) as
`manufactured
`in Beerse, Belgium
`
`
`
`
`
`
`
`
`
`
`
`
`
`1
`
`1
`
`1
`1
`
`3
`
`1
`
`
`
`
`
`
`
`Adequate
`
`07/18/2008
`
`T. Ocheltree
`David Claffey
`
`Adequate
`
`07/14/2008
`
`T. Ocheltree
`
`
`Adequate
`Adequate
`
`
`
`07/14/2008
`
`David Claffey
`By T. Ocheltree
`
`Adequate
`
`06/25/2008
`
`By Y. Sun
`
`Adequate
`
`06/03/2008
`
`By J. Metcalfe
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1 Action codes for DMF Table:
`1 – DMF Reviewed.
`Other codes indicate why the DMF was not reviewed, as follows:
`2 –Type 1 DMF
`3 – Reviewed previously and no revision since last review
`4 – Sufficient information in application
`5 – Authority to reference not granted
`6 – DMF not available
`7 – Other (explain under "Comments")
`
` 2
`
` Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did
`not need to be reviewed)
`
`B. Other Documents: N/A
`
`
`
`Page of 55 6
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`
`
`
`
`
`
`18. STATUS:
`
`
`ONDC:
`CONSULTS/ CMC
`RELATED
`REVIEWS
`Biometrics
`EES
`
`Pharm/Tox
`
`Biopharm
`LNC
`
`CDRH
`Microbiology
`
`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`RECOMMENDATION
`
`DATE
`
`REVIEWER
`
`
`Acceptable
`Acceptable
`Approval
`recommendation
`acceptable
`Provided
`recommendation
`Acceptable
`Approval
`recommendation
`
`
`
`Shawnte Adams
`15 APR 2008
`E Johnson
`2 JUL 2009
`17 JUN 2009 Elzbieta Chalecka-Franaszek
`
`01-AUG-2008
`
`
`
`John Duan
`Refer to review
`
`6 MAY 2009 William Burdick
`30 JUN 2008
`John Metcalf
`4 May 2009
`(Cork Site)
`
`
`
`Page of 55 7
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`The Chemistry Review for NDA 22-264
`
`The Executive Summary
`
` I. Recommendations
`
`
`
`
`A. Recommendation and Conclusion on Approvability
`
`Recommend approval from a CMC perspective.
`
`B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or
`Risk Management Steps, if Approvable
`
`On 20 JUL 2009 (N-0041) the applicant committed to adding “a clearly visible fill line to the
`syringe so that the health care provider can ensure that the syringes contain the required volume
`of suspension prior to administration and that no gross leakage or evaporation of the syringe
`contents has occurred during storage or shipping”.
`
`II. Summary of Chemistry Assessments
`
`A. Description of the Drug Product(s) and Drug Substance(s)
`Paliperidone is a selective, monoaminergic antagonist that exhibits the characteristic dopamine
`type 2 (D2) and serotonin (5-hydroxytrptamine [5-HT]) type 2A (5HT2A) antagonism of the
`newer second generation, antipsychotic drugs.
`
`Drug Product
`Paliperidone palmitate suspension for injection (F013) was developed as a monthly
`intramuscular injectable suspension for the treatment of schizophrenia. Each milliliter of
`paliperidone palmitate (156 mg/mL) is equivalent to 100 mg/mL of paliperidone. The drug
` and
`product was developed in six dosage strengths: 39 mg, 78 mg, 117 mg, 156 mg,
`234 mg of paliperidone palmitate (equivalent to 25 mg, 50 mg, 75 mg, 100 mg,
` and 150
`mg of paliperidone, respectively). This application proposes the marketing of all
`
`strength. The drug product is packaged in
` transparent cyclic olefin
`copolymer (COC) syringes and marketed as kit containing two needles for administration (a 22-
`g, 1½-inch safety needle and a 23-g, 1-inch safety needle).
`
`
`
`
`The extremely low solubility of paliperidone palmitate allows the formulation of an extended
`release product where the isotonic aqueous buffer solvent penetrates the muscle tissue and the
`undissolved paliperidone palmitate particles are localized at the site as a poorly soluble
`agglomerate. Paliperidone palmitate is stated to dissolve slowly after intramuscular injection
`before being hydrolyzed to paliperidone and absorbed into the systemic circulation.
`
`Stability data provided in the previous review cycle support a 24 month expiry period.
`
`
`
`Page of 55 8
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
`
`Drug Substance
`Paliperidone palmitate (R092670 drug substance) is the palmitate ester of paliperidone
`(R076477), the major active metabolite of risperidone. It is practically insoluble in aqueous
`media over a broad pH range. This low solubility allows the drug substance to be formulated as a
`suspension for intramuscular injection that provides an extended release profile that is a function
`of drug substance particle size. The drug substance particle size is controlled by the
`
` executed during the drug product manufacturing process to
`
`
`
` have been demonstrated to not impact drug product performance.
`All drug substance physiochemical information and manufacturing process information is
`referenced to DMF 20902.
`
`Summary of CMC related review issues addressed in the course of this review
`cycle:
`
`Complete response issues:
`
`
` previously found deficient. Holder resolved these
`CR #1: DMF
` for
`deficiencies to the satisfaction of the CDRH reviewer. It should be noted that the
`applicant committed to adding a fill line to the syringe barrel within 12 months of
`approval of this application (N-0041).
`
`CR #2: Strength needs to match the established name: The Division determined in
`consultation with the CDER Labeling and Nomenclature Committee and DMEPA that
`the strengths should be expressed in terms of the paliperidone palmitate rather than
`paliperidone. The applicant agreed to this change (labeling received 16 JUL 2009).
`Although many examples exist in approved products of name-strength mismatches and of
`the incomplete name of an ester being part of the established name, this decision is part
`of the current Agency policy to implement a uniform and consistent policy on this matter.
`
`CR#3: Genotoxic impurities issue: This issue was resolved by re-evaluation of the data
`by this reviewer and through the applicant agreeing to add a test for
`
` to the drug substance specification with a combined limit of
` ppm.
`
`
`CR#4: Addition of a specification for
` to the drug product specification. This
`issue was resolved by the applicants demonstration that their addition of citric acid
` through the expiry period.
`
`
`CR#5: The syringe barrel should contain calibrated markings to indicate the appropriate
`volume of the drug product in the syringe and allow for partial doses to be given from the
`syringe: this issue was resolved when the division agreed in the 28 NOV 2008 meeting
`that calibration markings would not be necessary (see meeting notes). A more detailed
`response regarding the addition of a fill line on the syringe barrel was provided in the 22
`
`
`
`Page of 55 9
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
`
`MAY 2009 amendment (detailed response to IR#6 and summary of fill line issue on next
`page).
`
`CR#6: A transparent label that allows for the viewing of the syringe calibration marks
`and drug product should be used for labeling of the syringes. As was agreed upon in
`response to CR#5, the calibrated markings would not be required, but the Agency
`requested that a fill line be added to the syringe barrels within 12 months of marketing
`approval. The applicant committed to doing so (email16 JUL 2009, amendment N-
`0041).
`
`
`Other CMC-related issues encountered during this review cycle:
`
`
`
`
`• Summary of genotoxin control issue: The CR letter included a request by the previous
`CMC reviewer (Dr. Terrence Ocheltree) to limit the levels of known genotoxins
`and
` to a level of
` ppm. This corresponded to a maximum daily exposure of
` During the course of this review cycle the applicant proposed amending the
`application with an additional 150 mg strength – therefore the recommended limit for
`genotoxins was lowered to
` ppm so that the maximum patient daily exposure would
`remain at the
`. The applicant proposed carrying out testing for genotoxin
` in the first ten commercial scale drug substance batches of intermediate ‘crude’
`drug substance then deleting this test if levels remained at acceptable levels. The
`applicant describes their “science-based” “criticality analysis” approach to determine
`critical steps and controls for drug substance manufacturing. This criticality analysis was
`supported by a “detailed knowledge of the origin and fate of impurities, including
`potentially genotoxic impurities”. However this ‘detailed knowledge” apparently did not
`include consideration of the
`of
` until the question was
`raised by the Agency in the 24 APR 2009 information request. One would assume that
`this should have been part of the most basic ‘criticality analysis’. The data provided did
`generally demonstrate that the synthetic process is capable of reducing levels of some or
`all of the genotoxin at laboratory and pilot scale. Three lots at commercial scale also
`showed levels of
` ppm of genotoxins. Although the latter are the most convincing
`data, it was in this reviewers evaluation that the experience to date remains limited and
`does not account for typical variations in the manufacturing environment (e.g. personnel
`and process variability). Further, the risk associated with these impurities is high as the
`harm that they have the potential to cause is both high and not immediately detectable by
`the patients. The burden on the applicant to test for these known genotoxins does not
`appear to be high relative to this risk. In this reviewer’s re-evaluation of the applicants
`responses and taking into consideration the synthetic process and the likely fate of
` and
` we requested that the applicant control (at drug substance release)
` and its
` to a combined level of
` ppm. The applicant accepted
`this recommendation in the 16 JUL 2009 amendment (N-0038).
`
`• Dosage form designation issue: the applicant proposed using
`the dosage form designation in the established name. This is in line with the other
`approved drug in this class of anti-psychotic depots – Risperdal Consta (risperidone)
`
` as
`
`
`
`
`
`Page of 55 10
`
`
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
` However in the Agency’s attempt to implement a more uniform and
`consistant policy in this matter, the Labeling and Nomenclature Committee
`recommended that the dosage form designation ‘extended-release injectable suspension’
`be used. “Injectable Suspension” is one of five acceptable dosage form designations
`listed in USP <1> and “extended release” is the only available modifier to indicate its
`prolonged release in the CDER Data Standard Manuel (DSM) . This recommendation
`was conveyed to the applicant during labeling negotiations. The applicant proposed the
`used of
` as there was no precedent in USP or DSM to use
`“extended release injectable suspension”. Further, they raised the possibility that if
`“extended release” were used that confusion would exist with the marketed INVEGA
`(paliperidone) extended-release tablets. The Agency acknowledged that “extended-
`release injectable suspension” is not mentioned in USP - as a monograph has not yet been
`produced for the single marketed product that uses this dosage form designation i.e.
`Vivitrol (naltrexone for extended release injectable suspension). In an attempt to
`differentiate the two “paliperidone” containing extended-release products, modifications
`of the propriatory name or the carton labels will be carried out in consultation with
`DMEPA (internal meeting 20 JUL 2009). The applicant accepted the use of the
`recommended dosage form designation (telcon 17 JUL 2009).
`
`•
`
`
`
`• Syringe Fill line issue: The applicant was asked to add a fill line to the syringe barrels.
`
`
`
`
`
`
` However these controls are not capable of detecting vials that leak after
`product release, either through a defect in the syringe, the plunger or the stopper. Such
`gross leaks may be detectable by the health care provider as the presence of white
`precipitate should be obvious. However, small leaks that result in leakage and/or
`evaporation of the water within the suspending medium would not be readily detected by
`the health care provider if a fill line were not present and the vial contents not visible.
`Further, such leaks could also result in microbial contamination of the drug product. It
`
`
`
`Page of 55 11
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
`
`should be stressed that data from batch release and stability studies provide no evidence
`that such leaks will routinely occur, however the risk to the patient is high as the
`detectability of such faults is low and severity of harm is high when one considers the
`indication and the relatively long period between treatments. It should be stressed that
`there are no known unique quality defects associated with this product above and beyond
`that of, for example, a typical tablet dosage form. Even in a six sigma process several
`defects per million are allowable, however, the end user generally has the opportunity to
`reduce this risk of quality defects further if a tablet appears cracked, speckled, or off-
`color. A clearly visible fill line will offer the end user of this product that same
`opportunity.
`It should be noted that in this reviewers non-exhaustive search of approved prefilled
`syringe products, all possessed either a fill line or graduations. Most products contained
`instructions for the health care provider to check that the level of liquid in the syringe is
`at or close to a fill line, or that it should be between two fill lines. Prefilled syringes are
`likely to occupy an increasing share of the US parenteral dosage form market due to their
`convenience, less waste of drug substance involved and technology-driven reductions in
`the cost of their production. Should this product have been approved as the applicant
`proposed, it would appear to be the first approved prefilled syringe without a fill line.
`Considering the nature of the proposed indication and the relatively lengthy time between
`administrations this reviewer does not consider the justifications provided for the absence
`of a fill line to be sufficient to set such a precedent. On 20 JUL 2009 (N-0041) the
`applicant committed to adding “a clearly visible fill line to the syringe so that the health
`care provider can ensure that the syringes contain the required volume of suspension
`prior to administration and that no gross leakage or evaporation of the syringe contents
`has occurred during storage or shipping”.
`
`
`
`
`
`
`
`
`• The applicant amended DMF 20902 to include the Cork site as a manufacturing site for
`“sterile grade” drug substance. Previously the Cork site manufactured the intermediate
`“crude” grade drug substance. This amendment was found to be acceptable by this
`reviewer. The Office of Compliance issued an ‘acceptable’ recommendation on 2 JUL
`2009.
`
`• Proposed marketing of the 234 mg dosage strength. This was found acceptable from a
`CMC perspective.
`
`• Clarification of accepted dissolution acceptance criteria: The CR letter contained the
`biopharm reviewer’s request that the applicant accept a version of the dissolution
`specification that lacked the initial 1.5 minute time point. This time point appeared to
`have been omitted as it was not part of the IVIVC as evaluated by the biopharm reviewer,
`but was a quality control to protect against ‘dose dumping’. The applicant agreed to
`accept this incomplete dissolution specification as part of their complete response.
`Clarification was sought from the applicant on this issue. They stated (telecon with PMQ
`Don Henry 14 JUL 2009) that the 1.5 minute time point was still in place and that the
`drug product specifications are unchanged from those proposed in the initial submission
`
`
`
`Page of 55 12
`
`

`

`
`
`
`
`
`
`
`
`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
`
`(Attachment 2 of this review). This adequately resolves this issue. We recommend that
`the following complete dissolution method be included in the action letter:
`
`Parameter
`Apparatus type:
`Media:
`Volume:
`Temperature:
`Frequency:
`Sampling Times:
`Acceptance
`Criteria:
`
`
`Analysis
`
`Dissolution Method and Specifications
`USP Type II (paddle)
`0.001 M HCl containing 0.489% Polysorbate 20 (Tween®20)
`900 ml
`25 ± 0.5 °C
`50 rpm
`1.5, 8, 20, and 45 minutes
`1.5 minutes NMT % of Label Claim
`8 minutes
` of Label Claim
`20 minutes
` of Label Claim
`45 minutes
` of Label Claim
`HPLC UV detection
`
`
`
`B. Description of How the Drug Product is Intended to be Used
`Treatment is initiated with a dose of 234 mg on treatment day 1 and 156 mg one week later,
`both administered in the deltoid muscle. The recommended monthly maintenance dose is
`117 mg; some patients may benefit from lower or higher maintenance doses within the
`recommended range of 39 mg to 234 mg based on individual patient tolerability and/or
`efficacy. Following the second dose, monthly maintenance doses can be administered in
`either the deltoid or gluteal muscle.
`The product is administered by intramuscular injection. For deltoid injection, a 1 ½-inch
`22G needle is recommended for patients ≥ 90 kg (≥ 200 lb) or a 1-inch 23G needle is
`recommended for patients < 90 kg (< 200 lb). For gluteal injection, a 1 ½-inch 22G needle
`is recommended regardless of patient weight.
`
`
`C. Basis for Approvability or Not-Approval Recommendation
`
`All outstanding CMC related issues contained in the CR letter and the information
`requests of 24 APR 2009 and 8 JUL 2009 have been resolved. DMF 20902 for the
`drug substance manufacture and DMF
` for the
` were found to be
`acceptable. The applicant accepted the proposed changes to the established name,
`labeled strengths and the control of genotoxic impurities. The Office of Compliance
`issued an acceptable recommendation on 2 JUL 2009. On 20 JUL 2009 (N-0041) the
`applicant agreed with the Agency recommendation to add “a clearly visible fill line to
`the syringe so that the health care provider can ensure that the syringes contain the
`required volume of suspension prior to administration and that no gross leakage or
`evaporation of the syringe contents has occurred during storage or shipping”.
`
`
`
`Page of 55 13
`
`(b) (4)
`
`(b) (4)
`
`(b) (4)
`
`(b)
`(4)
`
`(b) (4)
`
`(b) (4)
`
`

`

`
`CHEMISTRY REVIEW
`Executive Summary Section
`
`
`
`
`
`
`
`
`
`III. Administrative
`
`
`
`
`
`
`
`
`A. Reviewer’s Signature
`
`
`
`B. Endorsement Block
`
`ChemistName/Date: Same date as draft review
`ChemistryTeamLeaderName/Date
`ProjectManagerName/Date
`
`
`C. CC Block
`
`
`
`
`Page of 55 14
`
`41 pp withheld immediately following this page as (b)(4) CCI/TS.
`
`

`

`---------------------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`---------------------------------------------------------------------------------------------------------------------
` /s/
`---------------------
`David Claffey
`7/22/2009 10:18:28 AM
`CHEMIST
`
`Thomas Oliver
`7/22/2009 11:05:08 AM
`CHEMIST
`
`

`

`CHEMISTRY REVIEW
`
`
`
`
`
`
`
`
`
`NDA 22-264
`
`
`INVEGA® SUSTENNA (paliperidone palmitate) Injection
`
`
`Janssen Pharmaceutica N.V.
`
`
`
`
`Terrance Ocheltree, R.Ph., Ph.D.
`
`
`Office of New Drug Quality Assessment
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`
`Table of Contents
`
`
`Table of Contents .........................................................................................................2
`
`Chemistry Review Data Sheet.....................................................................................3
`
`The Executive Summary .............................................................................................7
`
`I. Recommendations..........................................................................................................................7
`A. Recommendation and Conclusion on Approvability............................................................................ 7
`B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk
`Management Steps, if Approvable........................................................................................................ 7
`
`II. Summary of Chemistry Assessment ..............................................................................................7
`A. Description of the Drug Product(s) and Drug Substance(s) .................................................................. 7
`B. Description of How the Drug Product is Intended to be Used............................................................... 8
`C. Basis for Approvability or Not-Approval Recommendation................................................................. 8
`
`III. Administrative...............................................................................................................................9
`A. Reviewer’s Signature............................................................................................................................. 9
`B. Endorsement Block................................................................................................................................ 9
`C. CC Block............................................................................................................................................... 9
`
`Chemistry Assessment...............................................................................................10
`
`I. Review of Common Technical Document-Quality (Ctd-Q) Module 3.2: Body of Data.............10
`S DRUG SUBSTANCE [Paliperidone palmitate, Janssen Pharmaceutica, N.V.] .................................... 10
`P DRUG PRODUCT [Paliperidone Palmitate Suspension for Injection, Johnson & Johnson]................ 12
`P.2 Pharmaceutical Development ..................................................................................................................... 14
`P.3 Manufacture................................................................................................................................................ 32
`P.4 Control of Excipients.................................................................................................................................. 41
`P.5 Control of Drug Product............................................................................................................................. 41
`P.6 Reference Standards or Materials............................................................................................................... 54
`P.7 Container Closure System .......................................................................................................................... 54
`P.8 Stability ...................................................................................................................................................... 58
`A APPENDICES....................................................................................................................................... 63
`R REGIONAL INFORMATION.............................................................................................................. 63
`
`II. Review of Common Technical Document-Quality (Ctd-Q) Module 1.........................................64
`A. Labeling & Package Insert ................................................................................................................... 64
`B. Environmental Assessment or Claim of Categorical Exclusion ......................................................... 67
`
`
`Page 2
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`Chemistry Review Data Sheet
`
`
`
`
`1. NDA 22-264
`
`
`2. REVIEW #1
`
`
`3. REVIEW DATE: 10-AUG-2008
`
`
`4. REVIEWERS: Terrance Ocheltree, R.Ph., Ph.D.
`
`
`5. PREVIOUS DOCUMENTS:
`
`
`Previous Documents
`IND 67356
`
`
`
`
`
`
`
`
`
`
`Document Date
`05/06/2003
`
`Document Date
`10/26/2007
`05/29/2008
`06/13/2008
`07/02/2008
`07/11/2008
`
`
`
`
`6. SUBMISSION(S) BEING REVIEWED:
`
`
`Submission(s) Reviewed
`Original (CMC)
`Amendment (BC)
`Amendment (BC)
`Amendment (BL)
`Amendment (BC)
`
`
`
`
`7. NAME & ADDRESS OF APPLICANT:
`
`
`
`Address:
`
`Name: Janssen, L.P.
`Johnson & Johnson Pharmaceutical Research &
`Development, LLC
`Office 12607, 1125 Trenton-Harbourton Road,
`Titusville, NJ 08560
`Kelly Ward (for CMC related issues)
`Cross-Pharma CMC Regulatory Affairs
`e-mail: kward1@prdus.jnj.com
`Telephone: 609-730-2056 (phone)
`609-730-2706 (fax)
`
`Representative:
`
`Page 3
`
`
`
`
`

`

`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`8. DRUG PRODUCT NAME/CODE/TYPE:
`
`
`a) Proprietary Name: INVEGA® SUSTENNA
`Non-Proprietary Name (USAN): Paliperidone palmitate
`Code Name/# (ONDC only): JNJ16977831; R092670
`b) Chem. Type/Submission Priority (ONDC only):
`• Chem. Type: 2
`• Submission Priority: S
`
`
`
`9. LEGAL BASIS FOR SUBMISSION: 505(b)(1)
`
`
`10. PHARMACOL. CATEGORY: Antipsychotic
`
`
`11. DOSAGE FORM:
`
`
`12. STRENGTH/POTENCY: 39 mg, 78 mg, 117 mg, and 156 mg of paliperidone
`palmitate, equivalent to 25 mg, 50 mg, 75 mg, and 100 mg of paliperidone,
`respectively
`
` Suspension for Injection
`
`
`
`
`
`
`
`13. ROUTE OF ADMINISTRATION: Intramuscular injection
`
`
`14. Rx/OTC DISPENSED: _X_Rx ___OTC
`
`
`15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
`
`
`
` SPOTS product – Form Completed
`
` X Not a SPOTS product
`
`
`
`16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR
`FORMULA, MOLECULAR WEIGHT:
`(9RS)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-4-oxo-6,7,8,9-
`tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate
`(±)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-
`4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl hexadecanoate
`
`
`
`Page 4
`
`

`

`
`
`
`
`
`
`CHEMISTRY REVIEW
`Chemistry Review Data Sheet
`
`
`
`
`The empirical formula is: C39H57FN4O4
`
`The molecular weight is: 664.89
`
`
`17. RELATED/SUPPORTING DOCUMENTS:
`
`A. Supporting DMFs:
`
`DMF # TYPE
`20902
`II
`
`HOLDER
`Janssen
`Pharmaceutica,
`N.V.
`Janssen
`Pharmaceutica,
`N.V.
`
`ITEM REFERENCED
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket